Lukyanenko Valeriy
University of Maryland Biotechnology Institute, Medical Biotechnology Center, 725 W. Lombard St., Rm S216, Baltimore, MD 21201, USA.
Nanomedicine (Lond). 2007 Dec;2(6):831-46. doi: 10.2217/17435889.2.6.831.
Cardiovascular disease, including heart failure, is one of the leading causes of mortality in the world. Delivery of nano-objects as carriers for markers, drugs or therapeutic genes to cellular organelles has the potential to sharply increase the efficiency of diagnostic and treatment protocols for heart failure. However, cardiac cells present special problems to the delivery of nano-objects, and the number of papers devoted to this important area is remarkably small. The present review discusses fundamental aspects, problems and perspectives in the delivery of nano-objects to functional sub-domains of failing cardiomyocytes. What size nano-objects can reach cellular sub-domains in failing hearts? What are the mechanisms for their permeation through the sarcolemma? How can we improve the delivery of nano-objects to the sub-domains? Answering these questions is fundamental to identifying cellular targets within the failing heart and the development of nanocarriers for heart-failure therapy at the cellular level.
心血管疾病,包括心力衰竭,是全球主要的死亡原因之一。将纳米物体作为标志物、药物或治疗基因的载体递送至细胞器,有可能大幅提高心力衰竭诊断和治疗方案的效率。然而,心脏细胞给纳米物体的递送带来了特殊问题,且致力于这一重要领域的论文数量非常少。本综述讨论了将纳米物体递送至衰竭心肌细胞功能亚结构域的基本方面、问题和前景。多大尺寸的纳米物体能够到达衰竭心脏的细胞亚结构域?它们穿过肌膜的机制是什么?我们如何改善纳米物体向亚结构域的递送?回答这些问题对于确定衰竭心脏内的细胞靶点以及在细胞水平开发用于心力衰竭治疗的纳米载体至关重要。